Aims: To report the anatomic and visual outcome of subfoveal and juxtafoveal choroidal neovascularization (CNV) in highly myopic eyes treated by intravitreal bevacizumab.
Methods: Prospective, non randomized, multicentric, interventional pilot study. Twenty-nine highly myopic eyes from 28 patients with subfoveal and juxtafoveal CNV were treated by three monthly intravitreal injections with 1.25 mg bevacizumab. Patients were evaluated for best corrected visual acuity (BCVA) and optical coherence tomography (OCT) at baseline and then monthly.
Results: Patients averaged 50 years of age (SD 15, range 29 to 82). LogMAR BCVA at baseline averaged 0.55 (SD 0.25, range 0.2 to 1.0) and 0.38 (SD 0.32, range 0.0 to 1.2) at month twelve. Sixteen eyes were naïve for treatment and 13 eyes had been previously treated by photodynamic therapy (PDT) (average 2.5 PDT sessions). Leakage from CNV had ceased in all eyes at month three. Six eyes needed one re-injection during follow-up at month 4 (one eye), 6 (four eyes) and 12 (one eye). Neither ocular nor systemic safety issues appeared during follow-up.
Conclusions: Intravitreal bevacizumab seems to be an effective and safe therapeutic procedure to treat subfoveal and juxtafoveal CNV in highly myopic eyes. Further studies are required to verify the efficacy and usefulness of this therapy compared with established treatments for this condition.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.